SABCS

Eric P. Winer, MD: Endocrine Therapy For Breast Cancer – Looking Into the Future
Jan
13
2012

  Dr. Eric Winer presented one of the plenary sessions at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. His talk was on endocrine therapy and looking into the future. His prognosis asks the question: Why haven’t we done better? And he addresses, what he believes, are the three key issues. Dr. Winer is […]

Read More
Eric P. Winer, MD: Medical Economics – The Cost of Care
Jan
13
2012

  Dr. Eric Winer moderated a panel at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium focusing on medical economics and the cost of cancer care. How do we begin to address these issues? Dr. Winer is Chief of Women’s Cancers at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. […]

Read More
Robert A. Hiatt, MD, PhD: Institute of Medicine Report (IOM) – Breast Cancer & the Environment
Jan
13
2012

  Dr. Robert A. Hiatt discusses the Institute of Medicine Report on Breast Cancer and the Environment: A Life-Course Approach, presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. The report urges a life-course approach to studying breast cancer because new information suggests that women and girls might be more susceptible to some […]

Read More
Julie R. Gralow, MD: SWOG SO226 Trial and Bisphosphonates Update
Jan
13
2012

Dr. Julie R. Gralow discusses the SWOG SO226 where postmenopausal women with metastatic breast cancer given first-line treatment of fulvestrant (Faslodex) and anastrozole (Arimidix) have a better progression-free survival (PFS) than those given anastrozole alone. She also gives an update on bisphosphonates and osteonecrosis of the jaw at the 34th Annual CTRC-AACR San Antonio Breast […]

Read More
Clifford A. Hudis, MD: What’s New With Chemotherapy Trials?
Jan
13
2012

  Dr. Clifford Hudis discusses what’s new with chemotherapy trials at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. He reviews eight posters from the conference that explored various chemotherapy-related questions. Dr. Hudis is the Chief, Breast Cancer Medicine Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill-Cornell Medical College […]

Read More
Clifford A. Hudis, MD: The Value of Progression-Free Survival (PFS)
Jan
13
2012

  Dr. Clifford Hudis, through his discussion of the trial showing bevacizumab (Avastin) slows metastatic breast cancer, he highlights the important topic of the value of progression-free survival (PFS). This interview was conducted at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. Dr. Hudis is the Chief, Breast Cancer Medicine Service at Memorial Sloan […]

Read More
Clifford A. Hudis, MD: Brain Metastasis and Breast Cancer
Jan
13
2012

  Dr. Clifford Hudis discusses brain metastasis and a clinical trial ongoing at Memorial Sloan Kettering Cancer Center where researchers are testing chemotherapy penetration to the brain in a select group of trial-qualifying patients. This interview was conducted at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. Dr. Hudis is the Chief, Breast Cancer […]

Read More
Hope Rugo, MD: Advances and Challenges In the Treatment of Metastatic Breast Cancer
Jan
13
2012

  Dr. Hope Rugo discusses the chemotherapy agent, Eribulin and the results of a recent study focused on breast cancer patients with advanced disease. We also question if she thinks this is the end for chemotherapy agents in the treatment of breast cancer? This interview was conducted at the 34th Annual CTRC-AACR San Antonio Breast […]

Read More
Hope Rugo, MD: Chemotherapy Agents and Breast Cancer Treatment
Jan
13
2012

  Dr. Hope Rugo discusses the chemotherapy agent, Eribulin and the results of a recent study focused on breast cancer patients with advanced disease. We also question if she thinks this is the end for chemotherapy agents in the treatment of breast cancer? This interview was conducted at the 34th Annual CTRC-AACR San Antonio Breast […]

Read More
Ann Partridge, MD, MPH: Treatment of Young Women With Breast Cancer
Jan
13
2012

  Dr. Ann Partridge discusses the differences, biologically, medically, and emotionally, in young women with breast cancer as compared to older women with breast cancer at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. Dr. Partridge is the Clinical Director, Breast Oncology Center and Director, Program For Young Women With Breast Cancer at the […]

Read More